• Menu
    • Search
    • Stock Code: 00512.HK
    • About Us
      • Company Profile
      • Company History
      • Enterprise Members
    • Product Center
      • Pharmaceutical Preparations
      • Medical Devices
      • Bio-technology Products and Health Products
      • Specialized Pharmaceutical Raw Materials and Other Products
      • Innovative Pipeline
    • Investor Relations
      • Information Disclosure
      • Corporate Governance
      • Stock Info
      • Contact Information
    • News & Media
      • Corporate News
      • Media Reports
      • Monthly Newsletter
    • Contact Us
      • Contact Information
      • Privacy Protection
    • Language
      • EnglishEnglish
      • 繁体中文繁体中文
      • 简体中文简体中文
  • English English
    • EnglishEnglish
    • 繁体中文繁体中文
    • 简体中文简体中文
  • Stock Code: 00512.HK

Stock Infomation

  • Home
  • Stock Infomation
Contact Us

Units 3302, 33/F, The Center, 99 Queen's Road Central, Hong Kong

ir@chinagrandpharm.com

www.chinagrandpharm.com

Pages Links

Company Profile

Product Center

Investor Relations

News & Media

Stock Info

Contact Us

Privacy

Legal Statement

Recent News
  • GP (HK) Announces Positive Profit Alert The Expected Increase in Consolidated Net Profit Attributable to Owners of the Company for FY2020 No Less Than 40%

    2021-2-21

  • First Patient Dosed in the Phase 1b Clinical Trial for Sepsis of GP (HK)’s World-Class Innovative Drug STC3141 Promote Commercialization of Technological Innovation Pipelines Globally at Full Speed First-mover Advantages in Anti-virus and Anti-infection Area Come into Play

    2020-12-13

© 2021. China Grand Pharmaceutical and Healthcare Holdings Limited All Rights Reserved.